|
Correct Answer » B
Explanation
|
|
Clinical Reasoning for the Correct Answer
– Statements 1 and 2 are correct:
– Adiponectin is an adipokine; its levels decrease in obesity.
– Orlistat is a reversible gastrointestinal (GI) lipase inhibitor, used to reduce fat absorption and treat obesity.
Why Option A is correct:
– Selects only statements 1 and 2, which are factually true for obesity.
Why Option B is incorrect:
– Statement 3 is incorrect:
– Liraglutide (a GLP-1 agonist) causes weight loss, not gain.
– Liraglutide is therefore recommended for weight management in obese T2DM patients.
Why Option C is incorrect:
– Includes statement 3 (incorrect as above).
– Excludes statement 1, which is correct.
Why Option D is incorrect:
– Statement 4 is incorrect:
– Bariatric surgery is generally recommended for BMI ≥40 kg/m², or ≥35 kg/m² with comorbidities, not >30 kg/m².
Why statement 1 is correct:
– Obesity is associated with low adiponectin levels; adiponectin is cardio-protective and insulin-sensitizing.
Why statement 2 is correct:
– Orlistat inhibits pancreatic & gastric lipases reversibly, decreasing triglyceride breakdown and fat absorption.
Why statement 3 is incorrect:
– Liraglutide is a GLP-1 receptor agonist that induces satiety, reduces weight, and is preferred in obese diabetics.
Why statement 4 is incorrect:
– Bariatric surgery thresholds: BMI ≥40, or BMI ≥35 with comorbidities (e.g., uncontrolled T2DM). Not routinely for BMI >30.
High‑Yield Synopsis:
Obesity—Key Facts
– Etiology & Pathogenesis
– Multifactorial: genetics, environment, lifestyle.
– Characterized by excessive accumulation of adipose tissue.
– Clinical Features
– Increased body fat, insulin resistance, metabolic syndrome risk.
– Diagnostic Findings
– Reduced adiponectin levels (protective adipokine).
– Elevated leptin (but leptin resistance).
– Pharmacologic Management
– Orlistat: reversible GI lipase inhibitor; reduces dietary fat absorption.
– Liraglutide: GLP-1 agonist; promotes weight loss in T2DM and obesity.
– Lorcaserin, phentermine/topiramate: also used, with indications and contraindications.
– Surgical Management
– Bariatric surgery indicated for:
– BMI ≥40 kg/m²
– BMI ≥35 kg/m² with serious comorbidities (e.g., T2DM, OSA).
– Not standard for BMI >30 kg/m² without comorbidities.